You are here

  • Home
  • Archive
  • Volume 11, Issue 4
  • Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma

Authors

  • Matthew R Woeste Department of Microbiology and Immunology, University of Louisville School of Medicine, Louisville, Kentucky, USA Division of Immunotherapy, The Hiram C. Polk Jr., MD Department of Surgery, Immuno-Oncology Program, Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Rejeena Shrestha Department of Microbiology and Immunology, University of Louisville School of Medicine, Louisville, Kentucky, USA Division of Immunotherapy, The Hiram C. Polk Jr., MD Department of Surgery, Immuno-Oncology Program, Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Anne E Geller Department of Microbiology and Immunology, University of Louisville School of Medicine, Louisville, Kentucky, USA Division of Immunotherapy, The Hiram C. Polk Jr., MD Department of Surgery, Immuno-Oncology Program, Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Shu Li Division of Immunotherapy, The Hiram C. Polk Jr., MD Department of Surgery, Immuno-Oncology Program, Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Diego Montoya-Durango Division of Immunotherapy, The Hiram C. Polk Jr., MD Department of Surgery, Immuno-Oncology Program, Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Chuanlin Ding Division of Immunotherapy, The Hiram C. Polk Jr., MD Department of Surgery, Immuno-Oncology Program, Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Xiaoling Hu Division of Immunotherapy, The Hiram C. Polk Jr., MD Department of Surgery, Immuno-Oncology Program, Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Hong Li Functional Immunomics Core, Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Aaron Puckett Functional Immunomics Core, Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Robert A Mitchell Division of Immunotherapy, The Hiram C. Polk Jr., MD Department of Surgery, Immuno-Oncology Program, Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Traci Hayat Division of Surgical Oncology, The Hiram C. Polk Jr., MD Department of Surgery, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Min Tan Division of Surgical Oncology, The Hiram C. Polk Jr., MD Department of Surgery, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Yan Li Division of Surgical Oncology, The Hiram C. Polk Jr., MD Department of Surgery, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Kelly M McMasters Division of Surgical Oncology, The Hiram C. Polk Jr., MD Department of Surgery, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Robert C G Martin Division of Surgical Oncology, The Hiram C. Polk Jr., MD Department of Surgery, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles
  • Jun Yan Department of Microbiology and Immunology, University of Louisville School of Medicine, Louisville, Kentucky, USA Division of Immunotherapy, The Hiram C. Polk Jr., MD Department of Surgery, Immuno-Oncology Program, Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky, USA PubMed articlesGoogle scholar articles

Citation

Woeste MR, Shrestha R, Geller AE, et al
Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma
Journal for ImmunoTherapy of Cancer 2023;11:e006221. doi: 10.1136/jitc-2022-006221
Online issue publication 
December 07, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.